ANDA 202145, held by Glenmark Pharms Ltd. Hydrocortisone Butyrate.
As of Nov 16, 2026, ANDA 202145 (Hydrocortisone Butyrate), held by Glenmark Pharms Ltd, was first approved by FDA on Sep 27, 2013, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 27, 2013 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · cream;topical | Hydrocortisone Butyrate | Discontinued |
| Jan 8, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 27, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters